Biotech Specialty Pharma

Clearant, Inc.

1801 Avenue of the Stars, Suite 435
Los Angeles, CA 90067 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Pathogen inactivating technology for the reduced contamination of biological products

Management Jon M. Garfield, Chief Executive Officer
Susan Etzel, CFO

Click here for Financial Data
Keywords: acl reconstruction recovery, acl replacement, acl surgery recovery time, acl repair surgery, cruciate knee ligament, pathogen inactivation technology, tissue allograft implants, plasma therapies, blood products, recombinant products, sterilization


Updated: Aug. 22, 2013


Clearant Corporation, a biotechnology company, develops and markets pathogen inactivation technology. The Clearant Process reduces the risk of contamination of biological products.......view more

Products / Services

The Clearant Process substantially inactivates all types of known pathogens for products across a variety of market segments, including plasma therapies, tissue allograft implants, recombinant product......view more

Technology / Differentiation

The Clearant Process is based on gamma-irradiation technology that delivers a predetermined amount of radiation to inactivate a desired level of pathogens. This process reduces the risk of contaminati...view more

Market / Customers

Two million Americans undergo orthopedic and spinal surgeries that could be made safer with the company's technology. The Process is intended to address safety concerns regarding allografts and certai......view more


Clearant will continue to add license agreement in its existing markets. Additionally, Clearant intends to generate recurring revenues from irradiation services. In September 2005, Clearant launched a...view more


In February 2008, Clearant announced that it had been selected by Millennium Surgical Center of Cherry Hill, New Jersey, as its primary source of allograft tissue for use in reconstructive knee surger...view more

...view more